In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization.
Chaetomium is an unusual etiological agent of human infections, but the mortality rate among immunocompromised patients is considerably greater than that among nonimmunocompromised individuals. We investigated the in vitro antifungal susceptibilities to novel antifungal agents of 19 strains belonging to three species of Chaetomium which have been involved in human infections, i.e., Chaetomium globosum, C. atrobrunneum, and C. nigricolor, and one strain of the closely related species Achaetomium strumarium. A modification of the NCCLS reference microdilution method (M38-A) was used to evaluate the in vitro activities of ravuconazole, voriconazole, albaconazole, and micafungin. Micafungin was not active at all, while the geometric mean MICs and minimum effective concentrations of the three triazoles were less than 0.5 and 0.4 micro g/ml, respectively.
D000935:Antifungal Agents / Q000494:pharmacology*; D002597:Chaetomium / Q000187:drug effects* / Q000235:genetics; D015169:Colony Count, Microbial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D003904:Mitosporic Fungi / Q000187:drug effects / Q000302:isolation & purification; D011743:Pyrimidines / Q000494:pharmacology; D012015:Reference Standards; D013844:Thiazoles / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D013844:Thiazoles; D014230:Triazoles; C104066:ER 30346; D065819:Voriconazole